ReviewVirchows Archiv : an international journal of pathology2003
CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.
Review in Virchows Archiv : an international journal of pathology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Mice lacking functional CD95-ligand display reduced proliferation of the intestinal epithelium without gross homeostatic alterations.Medical molecular morphology · 2016Article
- Mechanisms of methicillin-resistant Staphylococcus aureus pneumonia-induced intestinal epithelial apoptosis.Shock (Augusta, Ga.) · 2012Article
- Chestnut extract induces apoptosis in AGS human gastric cancer cells.Nutrition research and practice · 2011Article
- Fas ligand expression in lynch syndrome-associated colorectal tumours.Pathology oncology research : POR · 2009Article
- Epithelial apoptosis in mechanistically distinct methods of injury in the murine small intestine.Histology and histopathology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD95 is a member of the tumor necrosis factor receptor family. It is constitutively expressed on the basolateral membrane of intestinal epithelial cells (IEC) and induces apoptosis when cross-linked by its natural ligand, CD95L. The significance of providing such a death-inducing mechanism in IEC is not yet clear. In recent years a multitude of studies have been published addressing the question of where and under which conditions CD95L is produced in the gut in the normal and neoplastic situation. Although some of these studies have considerably influenced our view on the role of the CD95/CD95L system, it appears necessary to critically review published data which are in part confusing and contradictory. To date compelling evidence of CD95L expression in untransformed IEC is lacking, and involvement of the CD95/CD95L system in the physiological epithelial cell turnover appears unlikely. Whereas CD95L is overexpressed in T-cells under inflammatory conditions, its significance for mucosal damage in inflammatory bowel diseases is obscured by possible redundancies in cell death mechanisms. Finally, recent data indicate that the intriguing CD95L counterattack concept in gastrointestinal tract cancer needs to be revised.
Indexed as
Identifiers
12647210What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.